Q&A

Mycoplasmal Contamination And Its Impact On The Biopharma Industry

Source: Bionique Testing Laboratories, Inc.

A Q&A With Daniel Lundin, Founder, President, and CEO of Bionique Testing Laboratories, Inc.

Daniel Lundin has over 35 years of experience in cell biology. Since 1990, he has served as president of Bionique Testing Laboratories, an independent contract biotechnology firm specializing in the testing of cell cultures, biologicals, vaccines, and media/sera for mycoplasmal contamination. From 1984 through 1990, he was director of technical services for Bionique Laboratories (the predecessor to Bionique Testing Laboratories).

Prior to joining Bionique, Lundin was laboratory supervisor at W. Alton Jones Cell Science Center, where he participated in the coordination of the cell and tissue culture courses. Outside of the company, Lundin engages in economic development and strategic planning activities directed towards developing and attracting science and technology firms within the Adirondack Park in upstate New York.

In this Q&A, Lundin shares his insights on mycoplasma and its role in the biotechnology and pharmaceutical industries.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: